BIVIW BioVie Inc. Warrant
$0.25▲ +0.00%
Healthcare
Other
Volume 500
Avg Volume (10D) –
Key Metrics & Fundamentals
Market Cap
–
P/E Ratio
–
Div Yield
–%
52W Range
0.25 - 0.25
% vs 50 MA
-1.37%
% vs 200 MA
–%
RSI-14
49.2
MACD Histogram
+0.0000
Beta (1Y vs SPY)
2.88
Free Cash Flow
-$4.12M
Gross Rev
$0
Gross Profit
$0
EBITDA
-$5.64M
COGS
–
Operating Exp
$5.72M
Operating Income
-$5.72M
EBIT
-$5.72M
Pretax Income
-$5.65M
Net Income
-$5.65M
Price & Volume History
Loading chart…
Recent News
BioVie Invited to Present Data on Bezisterim in Long COVID at the NIH’s RECOVER-TLC Third Annual Workshop
GlobeNewswire · Oct 26, 2026 8:00 AM ET
BioVie reports positive Phase 2 Parkinson’s data for bezisterim
Proactive · Oct 20, 2026 9:53 AM ET
BioVie Presents Data on Bezisterim in Parkinson’s Disease at the 2026 American Neurological Association Annual Meeting
GlobeNewswire · Oct 20, 2026 8:00 AM ET
BioVie Presents Data on Bezisterim in Long COVID at the 2026 American Neurological Association Annual Meeting
GlobeNewswire · Oct 19, 2026 8:00 AM ET
BioVie to present Long COVID and Parkinson’s trial results at American Neurological Association meeting
Proactive · Oct 14, 2026 9:50 AM ET
BioVie to Present New Bezisterim Findings in Parkinson’s Disease and Long COVID at the 2026 American Neurological Association Annual Meeting
GlobeNewswire · Oct 14, 2026 8:00 AM ET
Financial Overview - Income Statement
Quarterly
No financial data available. Click Refresh on the ticker to load latest fundamentals.
See BIVIW's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.